Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phenlarmide Safety and PK in Early/Mid Parkinson's
NCT04693039Phase 1Completed
- Sponsor
- Yiling Pharmaceutical
- Start
- Feb 2021
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of phenlarmide in Parkinson's disease (PD) (8 arms), sponsored by Yiling Pharmaceutical. Primary endpoints: Dose Limiting Toxicity at 6 months, Maximum Tolerable Dose at 6 months and 4 more. Started Feb 2021; status: completed.
02
Drugs
phenlarmide
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT04693039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04693039.